STRIATED SKELETAL MUSCLE ANTIBODYASKA IFA IN DILUTIONS Test
Test Cost: AED 700.0
Test Name: STRIATED SKELETAL MUSCLE ANTIBODYASKA IFA IN DILUTIONS Test
Components: Price: 700.0 AED
Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Overnight fasting is preferred.
Report Delivery: Sample Tue / Sat by 9 am; Report 4 days
Method: Immunofluorescence Assay
Test Type: Myasthenia gravis
Doctor: Physician, Neurologist
Test Department: IMMUNOPATHOLOGY
Pre Test Information: Overnight fasting is preferred.
Test Details
The STRIATED/SKELETAL MUSCLE ANTIBODY (ASKA) IFA IN DILUTIONS test is a laboratory test that is used to detect the presence of antibodies against striated or skeletal muscle in a patient’s blood sample.
This test is performed using a technique called indirect immunofluorescence assay (IFA). In this test, the patient’s blood sample is diluted and incubated with a substrate that contains striated or skeletal muscle tissue. If antibodies against these tissues are present in the blood sample, they will bind to the muscle tissue in the substrate.
After incubation, the substrate is washed to remove any unbound antibodies. Then, a fluorescently labeled secondary antibody is added to the substrate. This secondary antibody will bind to any antibodies that are bound to the muscle tissue.
Finally, the substrate is examined under a fluorescence microscope. If antibodies against striated or skeletal muscle are present in the patient’s blood sample, they will appear as bright fluorescent spots or streaks on the muscle tissue in the substrate.
The results of the test are reported as the dilution at which the antibodies are detected. A positive result indicates the presence of antibodies against striated or skeletal muscle, which can be indicative of certain autoimmune or muscle-related disorders, such as myositis or muscular dystrophy.
It is important to note that this test is just one tool in the diagnostic process, and the results should be interpreted in conjunction with the patient’s symptoms, medical history, and other laboratory tests. A healthcare provider will be able to provide further guidance and interpretation of the test results.
Test Name | STRIATED SKELETAL MUSCLE ANTIBODYASKA IFA IN DILUTIONS Test |
---|---|
Components | |
Price | 700.0 AED |
Sample Condition | 2 mL (1 mL min.) serum from 1 SST. Shiprefrigeratedorfrozen.Overnight fastingispreferred. |
Report Delivery | Sample Tue / Sat by 9 am; Report 4 days |
Method | Immunofluorescence Assay |
Test type | Myasthenia gravis |
Doctor | Physician, Neurologist |
Test Department: | IMMUNOPATHOLOGY |
Pre Test Information | Overnight fasting is preferred. |
Test Details |
The STRIATED/SKELETAL MUSCLE ANTIBODY (ASKA) IFA IN DILUTIONS test is a laboratory test that is used to detect the presence of antibodies against striated or skeletal muscle in a patient’s blood sample. This test is performed using a technique called indirect immunofluorescence assay (IFA). In this test, the patient’s blood sample is diluted and incubated with a substrate that contains striated or skeletal muscle tissue. If antibodies against these tissues are present in the blood sample, they will bind to the muscle tissue in the substrate. After incubation, the substrate is washed to remove any unbound antibodies. Then, a fluorescently labeled secondary antibody is added to the substrate. This secondary antibody will bind to any antibodies that are bound to the muscle tissue. Finally, the substrate is examined under a fluorescence microscope. If antibodies against striated or skeletal muscle are present in the patient’s blood sample, they will appear as bright fluorescent spots or streaks on the muscle tissue in the substrate. The results of the test are reported as the dilution at which the antibodies are detected. A positive result indicates the presence of antibodies against striated or skeletal muscle, which can be indicative of certain autoimmune or muscle-related disorders, such as myositis or muscular dystrophy. It is important to note that this test is just one tool in the diagnostic process, and the results should be interpreted in conjunction with the patient’s symptoms, medical history, and other laboratory tests. A healthcare provider will be able to provide further guidance and interpretation of the test results. |